Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astria Therapeutics Inc ATXS

Healthcare Biotechnology
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a... see more

Recent & Breaking News (NDAQ:ATXS)

Catabasis Pharmaceuticals Reports Second Quarter 2016 Financial Results and Recent Corporate Highlights

Business Wire August 11, 2016

Catabasis Pharmaceuticals to Present at 2016 Wedbush PacGrow Healthcare Conference

Business Wire August 9, 2016

Catabasis Pharmaceuticals to Report Second Quarter 2016 Financial Results and Recent Corporate Developments on Thursday, August 11

Business Wire July 28, 2016

Catabasis Pharmaceuticals Names Joseph Johnston VP, Regulatory Affairs

Business Wire July 12, 2016

IR Prognosis Listed by Microsoft to Support Skype for Business Network Readiness Assessments

Business Wire July 12, 2016

Catabasis Pharmaceuticals Announces the Initiation of an Open-Label Extension for the MoveDMD® Trial Studying Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy

Business Wire July 7, 2016

Catabasis Pharmaceuticals to Present Edasalonexent (CAT-1004), an Oral Agent Targeting NF-kB: MoveDMDSM Trial in Duchenne Muscular Dystrophy (DMD) at the 2016 PPMD Annual Connect Conference

Business Wire June 20, 2016

Mid-Morning Market Update: Markets Open Higher; Lululemon Reports Mixed Q1 Results

Benzinga.com  June 8, 2016

Catabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on MoveDMDSM: A Clinical Trial of Edasalonexent (CAT-1004) in Boys with Duchenne Muscular Dystrophy

Business Wire June 8, 2016

Catabasis Pharmaceuticals Announces Top-Line Phase 2a Results for CAT-2054

Business Wire June 7, 2016

Catabasis Pharmaceuticals Presents Positive Pre-Clinical Data at Digestive Disease Week 2016; Data Support CAT-2054, a Phase 2 Asset, as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH)

Business Wire May 21, 2016

Catabasis Pharmaceuticals to Present CAT-2054, a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) and Hypercholesterolemia, at the National Lipid Association 2016 Scientific Sessions

Business Wire May 16, 2016

Catabasis Pharmaceuticals to Present Pre-Clinical Data Supporting CAT-2054 as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) at Digestive Disease Week 2016

Business Wire May 16, 2016

Catabasis Pharmaceuticals Reports First Quarter 2016 Financial Results and Recent Corporate Highlights

Business Wire May 12, 2016

Catabasis Pharmaceuticals to Report First Quarter 2016 Financial Results and Recent Corporate Developments on Thursday, May 12

Business Wire April 28, 2016

Catabasis Pharmaceuticals Initiates Part B of the MoveDMDSM Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy

Business Wire April 12, 2016

Catabasis Pharmaceuticals to Present at Needham and Company's 15th Annual Healthcare Conference

Business Wire April 7, 2016

Catabasis Pharmaceuticals Announces Additions to Board of Directors and the Formation of a Science and Technology Committee

Business Wire April 6, 2016

Catabasis Pharmaceuticals Announces Resignation of Chief Financial Officer

Business Wire April 1, 2016

Catabasis Pharmaceuticals Presents Positive CAT-1004 Data from Part A of the MoveDMDSM Trial at the 2016 Muscular Dystrophy Association Clinical Conference

Business Wire March 21, 2016